These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2322989)

  • 1. Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo.
    Chen G; Zeller WJ
    Cancer Chemother Pharmacol; 1990; 26(1):37-41. PubMed ID: 2322989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G; Zeller WJ
    Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo.
    Chen G; Zeller WJ
    Cancer Chemother Pharmacol; 1993; 33(2):157-62. PubMed ID: 8261576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide.
    Chen G; Pan QC
    Cancer Chemother Pharmacol; 1988; 22(4):303-7. PubMed ID: 2971467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.
    Bernges F; Zeller WJ
    J Cancer Res Clin Oncol; 1996; 122(11):665-70. PubMed ID: 8898976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enhancement of antitumor effect of cisplatin on human ovarian cancer by cyclosporin A in vitro and in vivo].
    Zhou Y; Chen H; Yang Q
    Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):25-8. PubMed ID: 8758815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
    Damia G; Tagliabue G; Zucchetti M; Davoli E; Sessa C; Cavalli F; D'Incalci M
    Cancer Chemother Pharmacol; 1992; 30(6):459-64. PubMed ID: 1394802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of antitumor effect of cisplatin against human ovarian carcinoma cells by mifepristone in vivo.
    Liu Y; Wang LL; Deng Y
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Mar; 23(3):242-4. PubMed ID: 12651241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and -resistant rat ovarian tumor cell lines.
    Chen G; Zeller WJ
    Cancer Lett; 1992 Oct; 67(1):27-33. PubMed ID: 1423242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.
    Chen G; Zeller WJ
    J Cancer Res Clin Oncol; 1990; 116(5):443-7. PubMed ID: 2121738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
    Chen G; Zeller WJ; Todorov DK
    Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice.
    Shalinsky DR; Bischoff ED; Gregory ML; Lamph WW; Heyman RA; Hayes JS; Thomazy V; Davies PJ
    Clin Cancer Res; 1996 Mar; 2(3):511-20. PubMed ID: 9816198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoresistance in rat ovarian tumours.
    Zeller WJ; Frühauf S; Chen G; Keppler BK; Frei E; Kaufmann M
    Eur J Cancer; 1991; 27(1):62-7. PubMed ID: 1826445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
    D'Incalci M; Colombo T; Ubezio P; Nicoletti I; Giavazzi R; Erba E; Ferrarese L; Meco D; Riccardi R; Sessa C; Cavallini E; Jimeno J; Faircloth GT
    Eur J Cancer; 2003 Sep; 39(13):1920-6. PubMed ID: 12932672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic potentiation of Cisplatin cytotoxicity by caffeine in a Cisplatin-resistant rat ovarian tumor-cell line.
    Chen G; Zeller W
    Int J Oncol; 1992 Jul; 1(2):129-34. PubMed ID: 21584521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of thaliblastine (NSC-68075) in experimental ovarian tumor cell lines sensitive and resistant to cisplatin.
    Chen G; Todorov DK; Zeller WJ
    Cancer Lett; 1992 Feb; 62(2):173-7. PubMed ID: 1531781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
    Chen G; Zeller WJ
    Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma.
    Liu Y; Chen L; He X; Fan L; Yang G; Chen X; Lin X; DU L; Li Z; Ye H; Mao Y; Zhao X; Wei Y
    Int J Gynecol Cancer; 2008; 18(4):652-9. PubMed ID: 17892458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer.
    Qi X; Song X; Liu P; Yi T; Li S; Xie C; Zheng Y; Bai Y; Sun C; Wei Y; Zhao X
    Oncol Rep; 2011 Sep; 26(3):703-10. PubMed ID: 21667029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.